

Cross Contamination

The new EU requirements for the use of multipurpose equipment

24-25 February 2015, Berlin, Germany

SPEAKERS:

Richard M. Bonner

Chairman of ECA and the European QP Association, formerly Eli Lilly, UK

Brendan Cuddy

Compliance and Inspection Sector European Medicines Agency (EMA)

Dr Andreas Flückiger

F. Hoffmann-La Roche, Switzerland

Dr Jean-Denis Mallet

ECA & former head of the AFSSAPS, France



Each participant receives an industrial guidance document on the derivation of ADE/PDE values

LEARNING GOALS:

- Most frequent findings during GMP Inspections
- Update on regulatory requirements including dedicated & shared facilities
- How to detect potential contamination risks
- How to minimize the risk of cross contamination
- Cross Contamination risks through:
 - Facility Design
 - HVAĆ
 - Equipment
- Toxicological risk evaluation
- Determination of cleaning limits: how much cross contamination is allowed?



Cross Contamination

24-25 February 2015, Berlin, Germany

Objectives

This GMP training course aims at unveiling possible risks of cross contamination during the production process of pharmaceutical products and APIs. This is especially important as chapters 3 and 5 of EU GMP Guideline are being updated with a new focus on the avoidance of cross contamination

Learn

- how to detect possible risks,
- how to avoid cross contamination,
- how to determine exposure limits.

Background

Cross Contamination is one of the highest risks for patients using pharmaceutical products. Not only the presence of small amounts of antibiotics or other highly potent compounds in medicines can cause severe damage but also carryover of products into another pharmaceutical product is of high risk to the patient. According to the Medicines & Healthcare Products Regulatory Agency in the United Kingdom Product contamination is the second to third highest reason for recalls in the UK in recent years.

It is therefore not surprising that the EU commission published an update of the chapters 3 (premises & equipment) and 5 (production) with the focus on minimizing the risk of cross contamination. Almost at the same time a new EMA Guide on setting health based exposure limits was published. This new guide has massive impact on the dedication of facilities and also on the calculation of limits for cleaning validation. The currently used 1/1000 dose or 10 ppm criteria will become completely obsolete.

Reasons for cross contamination can be manifold and caused by technical as well as organisational deficiencies. Insufficient cleaning of equipment, poor facility design or inappropriate design of the HVAC system may be reasons as well as contamination due via personnel or primary packing material. But also the design of the production process itself can be the cause for cross contamination, for example due to open product handling during transfer or sampling operations in shared plants.

It is therefore extremely important to avoid or minimise the risk of cross contamination, starting when process and equipment are designed. It is also important to learn how contamination risks can be detected, either by visits on-site or by reviewing of the documents which can be SOPs or technical drawings.

Target Group

Inspectors & QA staff are target group of this course but also responsible persons from production and engineering.

Programme

Cross Contamination: viewpoint from the authorities

Part A: Physical and chemical Contaminations - Most frequent Non-Compliances

- Poor practices observed
- Examples of deficiencies & recommendations
- Recalls related to cross contamination

Part B: Update on the regulatory requirements: EU GMP and usage of multipurpose equipment

- Dedicated vs shared facilities
- EU GMP-Guide chapters 3.6 and 5.17-21: what are the consequences
- Impact of the EMA guideline on setting health based exposure limits
- Risk Management

Principles of assessing toxicological risks – the basis for calculating limits

The toxicological and pharmacological basis of assessing APIs with the objective of worker protection is the same as the one justifying GMP cleaning validation criteria and acceptance of multi-product use of a facility.

- Assessing the hazard: potency and toxicity of the compounds. Occupational exposure limits and health hazard categories
- Definitions: ADE, PDE, NOEL, LOEL, OEB, OEL
- Classification of substances into hazard categories
- How is patient safety connected with the occupational exposure limit?
- Use of correction factors to fill data gaps

Cross Contamination through poor facility design and maintenance practices

- A model for identifying cross-contamination risks
- Cross-contamination due to poorly designed facilities (surfaces, cracks and other sources)
- Contamination and cross-contamination due to equipment and their maintenance
- Inadequate segregation of processes involving sensitising products from other products

Environmental Control - Cross Contamination Risks through failures in the HVAC System

- Airborne contamination and airborne cross-contamination
- Capture of contaminants where dust is generated
- Air handling and prevention of dust dissemination
- Failures in HVAC design (filtration, airflow pattern, pressure differentials)
- Failures in HVAC operation (e.g. energy saving, unbalanced pressure differentials)

Risk of Contamination in non-sterile production processes

- What is a risk-based approach to understanding contamination control? How do you decide if the risk is acceptable or not?
- Where can you apply Q9 principles to assess contamination risk during production?
 - In Drug substance manufacture
 - In Drug product manufacture and packaging
 - During sampling, weighing/material transfers
 - In the warehouse and distribution chain.

Contamination caused by inappropriate cleaning of equipment

- What is clean?
- What is "worst case"
- Inadequate cleaning procedures
- The use of non-validated cleaning practices
- The use of non-validated analytical test methods

How much cross contamination is allowed? Cleaning limits in accordance with the new EMA guideline

- Controlling cross contamination
- Old and new approach for the determination of cleaning validation limits
- Requirements from the new EMA Guideline on the setting of risk/health based limits
- RiskMaPP in the cleaning of pharmaceutical equipment
- Concrete examples / calculation examples

Workshop:

Calculation of cleaning validation limits according to the new EMA requirements

In this workshop you will learn how the new EMA guideline on setting health-based limits can be applied in practice. You will learn how to calculate substance-specific limits, also called ADEs (acceptable daily exposures) and PDEs (permitted daily exposures).

To do this, you will learn how to determine the right starting point for each calculation, the NOEL (No-observed-effect-level) and how correction factors are used.

Social Event



On Tuesday, 24 February 2015 you are cordially invited to a social event. This is an excellent opportunity to share your experiences with colleagues from other companies in a relaxed atmosphere.

Speakers



Richard M. Bonner

Chairman of ECA and the European QP Association, formerly with Eli Lilly, United Kingdom

Richard Bonner was a Senior Quality Adviser for Eli Lilly and Company. Mr Bonner is a

Qualified Person in Europe, Chairman of the ECA and of the Qualified Person Association Advisory Board. He has 31 years experience within the pharmaceutical industry and has been involved in multiple inspections from the MHRA & FDA and has also immense experiences as a GMP auditor.



Brendan Cuddy

Compliance and Inspection Sector European Medicines Agency (EMA)

Brendan Cuddy obtained degrees in Chemistry, Quality & Operations Management and also in Pharmaceutical Manufacturing

Technology. He joined the European Medicines Agency as Scientific Administrator in 2002. He is responsible for amongst other things co-ordination of GMP inspections and regulatory procedures relating to reports of defective medicinal products and GMP compliance problems. He is currently chairing a small working group of experts to implement the action plan identified in the EMA Reflection Paper on Medicinal Product Shortages due to manufacturing and quality problems.



Dr Jean-Denis Mallet

ECA, former head of the French Inspection Department AFSSAPS, NNE Pharmaplan Jean-Denis Mallet is a pharmacist. He was previously the Head of the Pharmaceutical Inspection Department at the French Health

Products Regulatory Agency (Afssaps). He also used to work in or with the pharmaceutical industry during many years at various positions including Quality Assurance, Production Management, Engineering and GMP Consulting. He has also been auditor of the International Red Cross. Now he is member of the ECA advisory board and works for NNE Pharmaplan.



Dr Andreas Flückiger

F. Hoffmann-La Roche
An occupational physician by training, Andreas Flückiger has been the head of the occupational health services of the Roche
Group for 20 years. He is active in leading

roles in numerous national and international associations such as the International Association for Occupational and Environmental Health in the Chemical Industry (Medichem), in the Scientific Committee of the European Council for Ecotoxicology and Toxicology of Chemicals (ECETOC).

Reservation Form: CONCEPT HEIDELBERG P.O. Box 10 17 64 69007 Heidelberg Germany



e-mail: info@conceptheidelberg.de

Internet: www.gmp-compliance.org

			`
L	20.		
τ,	3		

Reservation Form (Please complete in full)

If the bill-to-address deviates from the specifications on the right,

please fill out here:

24-25 February 2015, Berlin, Germany

Ms

ž

Cross Contamination

Country PO Number if applicable Department Fax Important: Please indicate your company's VAT ID Number Title, first name, surname Street/P.O. Box E-Mail (please Company Phone City Fax +49 (0) 62 21/84 44 34 CONCEPT HEIDELBERG

processing of this order, for which I hereby declare to agree that my personal data is stored and processed. Concept Heidelberg will only send me information in relation with this order or similar ones. My personal data will not be disclosed to third parties (see also the privacy policy at http://www.gmp-compliance.org/eca_privacy.html). I note that I can ask for the modification, correction or deletion of my data at any time via the contact form on this website.

med us, you will have to pay the full registration fee, even if have not made the payment yet. Only affer we have received have not are entitled to participate in the conference

your

and

an event. If the e soon as possible

will receive a full refund of fees paid. CONCEPT HEIDELBERG will not

be responsible for discount airfare penalties or other costs incurred

due to a cancellation.

Terms of payment: Payable without deduc-

Important: This is a binding registration and above fees are due in

case of cancellation or non-appearance. If you cannot take part,

your payment, you are entitled to participate in the conference (receipt of payment will not be confirmed)! (As of January 2012)

message. In case you do not appear at the event without having informed us, you will have to pay the full registration fee, even if

Date

Tuesday, 24 February 2015, 10.30 to approx. 18.00 h (Registration and coffee 10.00 - 10.30 h) Wednesday, 25 February 2015, 08.30 to approx.

Venue

Steigenberger Hotel Berlin Los-Angeles-Platz 1 10789 Berlin, Germany +49 (0)30 212 7 - 0 Phone +49 (0)30 212 7-799

Fees (per delegate plus VAT)

ECA Members € 1,490 APIC Members € 1,590 Non-ECA Members € 1,690 EU GMP Inspectorates € 845

The conference fee is payable in advance after receipt of invoice and includes conference documentation, lunch on both days, dinner on the first day and all refreshments. VAT is reclaimable.

Accommodation

CONCEPT HEIDELBERG has reserved a limited number of rooms in the conference hotel. You will receive a room reservation form when you have registered for the event. Please use this form for your room reservation to receive the specially negotiated rate for the duration of your stay. Reservation should be made directly with the hotel. Early reservation is recommended.

Registration

Via the attached reservation form, by e-mail or by fax message. Or you register online at www.gmp-compliance.org.

Conference Language

The official conference language will be English.

Organisation

CONCEPT HEIDELBERG P.O.Box 10 17 64 69007 Heidelberg, Germany, Phone ++49-62 21/84 44-0 Fax ++49-62 21/84 44 34 info@concept-heidelberg.de www.concept-heidelberg.de

For questions regarding content:

Dr Robert Eicher (Operations Director) at +49-62 21/84 44 12, or per e-mail at eicher@concept-heidelberg.de.

For questions regarding reservation, hotel, organisation etc.:

Mr Ronny Strohwald (Organisation Manager) at +49-62 21/84 44 51, or per e-mail at strohwald@concept-heidelberg.de.

2. If you have to cancel entirely we must charge the following processing fees: Cancellation

D-69007 Heidelberg

GERMANY

P.O. Box 101764

. We are happy to welcome a substitute colleague at any time. attend the conference you have two options: - within I week prior to the conference 100 % - until 2 weeks prior to the conference 10 %, - until 1 weeks prior to the conference 50 %

CONCEPT HEIDELBERG reserves the right to change the materials,